Relmada Therapeutics appoints Bipin Dalmia as Chief Business Officer

RELMADA THERAPEUTICS, INC.

Bipin Dalmia, PhD, MBA, appointed Chief Business Officer effective July 28, 2026.
He brings nearly three decades of biopharmaceutical leadership, with expertise in NMIBC and corporate strategy.
He will lead corporate strategy, commercial planning, and business development, reporting to CEO Sergio Traversa.
His appointment supports advancement of NDV-01, Relmada's sustained-release intravesical therapy for NMIBC.
He previously helped bring first FDA-approved intravesical gene therapy to bladder cancer patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.